GlobalData has prepared an analysis comparing the types of biosimilars investigated between 2007 and 2016.
This analysis revealed there was an increase in the initiation of antibody biosimilar trials in comparison with other biosimilar trials, from one in 2007 to 61 in 2016; a compounded annual growth of 58%. In comparison, other biosimilars had a more modest CAGR of 20% within this same period from eight trials started in 2007 versus 42 trials started in 2016.
Further analysis shows antibody biosimilar trials have had a general yearly upward trend, with only a slight dip between the years 2012 and 2013 from 27 to 26 trials; a decrease of approximately 4%. However, other biosimilar trials have seen larger dips, but with a longer recovery period back to the original number of trials before the decrease took place. Across the same period, antibody biosimilars lost one trial, whereas, other biosimilar trials had a decrease of eight, a dip of 22% in the total number of trials being initiated.
Figure 1 displays the growth of antibody versus other biosimilar clinical trials from 2007-2016
In Figure 1, Antibody biosimilar trials have made substantial gains over the years surpassing other biosimilar trials on two occasions. In 2014, 36 antibody trials were initiated, compared to 32 other biosimilar trials. In 2016, 61 antibody biosimilar trials were started in comparison to 42 other biosimilar trials; a difference of 45%. As a result, GlobalData expects the increase in the initiation of antibody biosimilar clinical trials to continue in the upcoming years, barring the passage of legislation containing any arduous regulatory requirements.
GlobalData believes as biosimilar pathways in countries around the world become more standardised, and with greater clarity, a larger number of such trials will be initiated.